Slovenská chirurgia 1/2015

Economic aspects of the treatment skin and soft tissue infections with anti-staphylococcal phage lyzate

Resistance of S. aureusto common used antibiotics represents big medical and economic issue. Authors measured acquisition cost during treatment of SSTI with anti-staphylococcal phage lyzate and common used parenteral antibiotics. Only treatment with cotrimoxazole was associated with lower acquisition cost than anti-staphylococcal phage lyzate acquisition cost. During simulation of real expenesies of 100 patients with SSTI acquisition cost of patients treated with anti-staphylococcal phage lyzate was lower than acquisition cost of antibiotics. Addition of anti-staphylococcal phage lyzate to the treatment of SSTI is effective when duration of total treatment is shortened in about 1,44 days in vancomycin regimen and in about 0,96 days in linezolid regimen.

Keywords: S. aureus, anti-staphylococcal phage lyzate, skin and soft tissue infections, acquisition cost, treatment economic aspects.